Atara Biotherapeutics (ATRA) Retained Earnings (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Retained Earnings came in at -$2.0 billion in Q1 2026, little changed YoY from -$2.0 billion in Q1 2025, and down 202601100.0% on a QoQ basis from $1000.0 in Q4 2025.
Atara Biotherapeutics (ATRA) Retained Earnings (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 14 years of Retained Earnings data on file, last reported at -$2.0 billion in Q1 2026.
- Quarterly Retained Earnings changed 0.47% year-over-year to -$2.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.0 billion (changed 0.47% YoY) and the FY2025 annual result came in at $1000.0, down 87.5% from the prior year.
- Retained Earnings eased to -$2.0 billion in Q1 2026, from $1000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $22000.0 in Q3 2024 to a low of -$2.0 billion in Q1 2026.
- A 5-year average of -$921.4 million and a median of -$768.2 million in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings tumbled 6743650.0% — and 2024, when it soared 103.85%.
- Tracing ATRA's Retained Earnings over 5 years: stood at -$2.1 million in 2022, then tumbled by 95166.09% to -$2.0 billion in 2023, then jumped by 100.0% to $8000.0 in 2024, then tumbled by 87.5% to $1000.0 in 2025, then plunged by 202601100.0% to -$2.0 billion in 2026.
- The last three Retained Earnings figures came in at -$2.0 billion (Q1 2026), $1000.0 (Q4 2025), and $2000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 4.38 Bn |
| 10 | Atara Biotherapeutics | 144.77 Mn | 128.22 Mn | 439,000.00 | -2.03 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.03 Bn |
| Mar 31, 2026 | -2.03 Bn |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Mar 31, 2025 | -2.02 Bn |
| Dec 31, 2024 | 8,000.00 |
| Sep 30, 2024 | 22,000.00 |
| Jun 30, 2024 | -2.02 Bn |
| Mar 31, 2024 | -2.00 Bn |
| Dec 31, 2023 | -1.97 Bn |
| Sep 30, 2023 | -571,000.00 |
| Jun 30, 2023 | -933,000.00 |
| Mar 31, 2023 | -1.24 Mn |
| Dec 31, 2022 | -2.07 Mn |
| Sep 30, 2022 | -1.62 Bn |
| Jun 30, 2022 | -1.53 Bn |
| Mar 31, 2022 | -1.55 Bn |
| Dec 31, 2021 | -368,000.00 |
| Sep 30, 2021 | 24,000.00 |
| Jun 30, 2021 | -1.29 Bn |